Founded in Ramsey, United States, ADMA Biologics is dedicated to developing plasma-derived biologics aimed at treating and preventing infectious diseases. The company's core mission is to enhance the lives of immunocompromised individuals and patients at risk for certain infections through innovative immunotechnology. ADMA Biologics offers a portfolio of FDA-approved immune globulin products and utilizes a proprietary microneutralization assay to measure neutralizing antibody levels.
Notable figures associated with ADMA Biologics include experienced professionals in the biopharmaceutical industry and key investors who have supported its mission. The company has achieved significant milestones, including the approval and commercialization of its immune globulin products. ADMA Biologics' impact is evident in its contribution to improving patient outcomes and advancing the field of plasma-derived therapeutics.
